No abstract

No abstract

Developing an initiative begun by Professor Peter Davies and colleagues in Liverpool in 2008, the BTS has now significantly increased the functionality of this Service to offer an opportunity for genuine on line dialogue between experts and service users on all aspects of the management of patients with MDRTB.Fully operational since July 2011-64 discrete case queries were received in the first year of operation, of which 41 were confirmed as MDRTB; 4 XDRTB; 7 Isoniazid mono-resistant and 1 related to a mycobacterium infection. The remaining 11 cases discussed were never confirmed as MDRTB or were general requests for advice.This represents a 45% increase in case discussion since the BTS unveiled the new Service and the initial post is now regularly being followed by further requests for help as new difficulties in case management emerge.The BTS MDRTB Clinical Advice Forum is accessible via a link on the home page of the BTS website OR directly at the url below: http://forums.brit-thoracic.org.uk/ After an on line registration is approved by the forum administrator, users are prompted to provide anonymised case details according to a pre-set questionnaire template. There is also a free text box and an opportunity to post X-ray and CT images.

IntroductionNICE 2016 Tuberculosis guidance recommends significant changes in contact screening. Tuberculin Skin Test (TST) is advocated for diagnosis of latent tuberculosis infection (LTBI), with a positive TST redefined as 5mm regardless of BCG status, IGRA only to be used in diagnostic uncertainty, upper age for LTBI treatment raised from 35 to 65, and contact tracing no longer recommended for extra-pulmonary TB.We use a 2 step test, with IGRA for those with TST > 10 mm in context of BCG, and treat LTBI on basis of IGRA result. We aimed to assess the implications for our service of adopting the new guidance.MethodsWe reviewed written and electronic records for all contacts screened in Leeds in 2015. NICE 2016 guidance was applied retrospectively to analyse the impact of each recommendation and the guidance as a whole.Results216 contacts were screened. Full records were available for 193. 14 were treated for LTBI, 2 for active TB, and 6 contacts over 35 had X-ray follow up. 34 had TST > 10 mm, an additional 13 had TST 5–9 mm. Of 34 with TST > 10 mm, 14 (41%) had positive IGRA. 97/193 (50%) were contacts of extrapulmonary tuberculosis. 4 of these were treated for LTBI, but 21 had TST > 5 mm.Using TST > 5 mm cut off would increase the number of IGRA tests from 34 to 46. Treating on basis of TST alone would increase the number given chemoprophylaxis from 14 to 46. Stopping screening for contacts of extrapulmonary cases would reduce the number screened by 50% and the number treated from 46 to 29. However, this would be at the cost of missing at least 4/14 LTBI with positive IGRA.ConclusionAdopting the new NICE guidance in full would reduce the number screened but significantly increase the numbers treated for LTBI. Using the 2 step test with a TST cut off of 5mm would modestly increase the number of IGRA tests but would be unlikely to have a large impact on the number treated. Stopping screening for contacts of extrapulmonary TB would reduce the screening workload by 50% but reduce the number of LTBI cases diagnosed by 29%.